Pulse Biosciences Stock Investor Sentiment

PLSE Stock  USD 16.99  0.14  0.82%   
About 55% of Pulse Biosciences' shareholders are presently thinking to get in. The analysis of overall sentiment of trading Pulse Biosciences stock suggests that some investors are interested at this time. The current market sentiment, together with Pulse Biosciences' historical and current headlines, can help investors time the market. In addition, many technical investors use Pulse Biosciences stock news signals to limit their universe of possible portfolio assets.
  

Pulse Biosciences Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Pulse Biosciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Pulse Biosciences Maximum Pain Price Across April 17th 2025 Option Contracts

Pulse Biosciences' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Pulse Biosciences close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Pulse Biosciences' options.
over six months ago at businesswire.com         
Pulse Biosciences Reports Business Updates and Fourth Quarter Full Year 2023 Financial Results
businesswire News
over six months ago at businesswire.com         
Pulse Biosciences Reports Business Updates and Fourth Quarter Full Year 2023 Financial Results
businesswire News
over six months ago at finance.yahoo.com         
Pulse Biosciences Reports Business Updates and Fourth Quarter Full Year 2023 Financial Results
Yahoo News
over six months ago at businesswire.com         
Pulse Biosciences Announces Plans to Initiate a Rights Offering
businesswire News
over six months ago at news.google.com         
Pulse Biosciences to Release Quarterly Earnings on Thursday - MarketBeat
Google News at Macroaxis
over six months ago at news.google.com         
Pulse Biosciences Stock Price Down 4.7 percent - MarketBeat
Google News at Macroaxis
over six months ago at news.google.com         
Were Not Very Worried About Pulse Biosciences Cash Burn Rate - Yahoo Movies Canada
Google News at Macroaxis
over six months ago at businesswire.com         
Pulse Biosciences Schedules Fourth Quarter Full Year 2023 Financial Results Conference Call for Marc...
businesswire News
over six months ago at news.google.com         
Pulse Biosciences Shares Gap Up to 9.64 - Defense World
Google News at Macroaxis
over a year ago at massdevice.com         
FDA clears pulsed field ablation electrode tech from Pulse Biosciences
news
over a year ago at investing.com         
FDA clears Pulse Biosciences soft tissue ablation system
Investing News at Macroaxis
over a year ago at businesswire.com         
Pulse Biosciences Announces FDA 510 Clearance for its CellFX nsPFA Percutaneous Electrode System
businesswire News
over a year ago at finance.yahoo.com         
Pulse Biosciences Announces FDA 510 Clearance for its CellFX nsPFA Percutaneous Electrode System
Yahoo News
over a year ago at businesswire.com         
Pulse Biosciences Announces FDA 510 Clearance for its CellFX nsPFA Percutaneous Electrode System
businesswire News
over a year ago at news.google.com         
Pulse Biosciences Inc Banking On FDA Approval - Insider Financial
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Pulse Biosciences that are available to investors today. That information is available publicly through Pulse media outlets and privately through word of mouth or via Pulse internal channels. However, regardless of the origin, that massive amount of Pulse data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Pulse Biosciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Pulse Biosciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Pulse Biosciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Pulse Biosciences alpha.

Pulse Biosciences Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Acquisition by Robert Duggan of 55256 shares of Pulse Biosciences at 17.18 subject to Rule 16b-3
12/13/2024
2
Disposition of 24656 shares by Robert Duggan of Pulse Biosciences at 11.0 subject to Rule 16b-3
12/18/2024
3
Acquisition by Paul LaViolette of 450000 shares of Pulse Biosciences at 18.43 subject to Rule 16b-3
01/08/2025
4
Pulse Biosciences Nanosecond PFA Technology to be Featured in Multiple Presentations at the AF Symposium
01/13/2025
5
Pulse Biosciences Inc Unveils Promising Data from Cardiac Catheter Study
01/21/2025
6
Acquisition by Zanganeh Mahkam of 30121 shares of Pulse Biosciences at 11.0 subject to Rule 16b-3
01/24/2025
7
Griffin Asset Management Inc. Has 4.14 Million Stake in Pulse Biosciences, Inc. - MarketBeat
01/28/2025
8
Pulse Biosciences Nanosecond PFA Technology to Be Featured in Presentations at North American Society for Interventional Thyroidology Annual Meeting
01/30/2025
9
Disposition of 30121 shares by Zanganeh Mahkam of Pulse Biosciences at 11.0 subject to Rule 16b-3
02/03/2025
10
Pulse Biosciences appoints Jon Skinner as CFO
02/04/2025
11
Acquisition by Van Den Broek Richard of 20000 shares of Pulse Biosciences at 14.55 subject to Rule 16b-3
02/11/2025
12
Pulse Biosciences Shares Down 7.8 percent - Heres Why - MarketBeat
02/20/2025
13
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635
03/04/2025
14
Pulse Biosciences Schedules Fourth Quarter Full Year 2024 Financial Results Conference Call for March 27, 2025
03/07/2025

Complementary Tools for Pulse Stock analysis

When running Pulse Biosciences' price analysis, check to measure Pulse Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pulse Biosciences is operating at the current time. Most of Pulse Biosciences' value examination focuses on studying past and present price action to predict the probability of Pulse Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pulse Biosciences' price. Additionally, you may evaluate how the addition of Pulse Biosciences to your portfolios can decrease your overall portfolio volatility.
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios